Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis
NCT00603785 · University of California, San Francisco · PHASE4 · withdrawn · last registry update 2020-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient funds available” | – | Registry record, University of California, San Francisco |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGHE within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-04Results posted on the registry: University of Colorado, Denver, Omalizumab (NCT01701583)
- 2020-11-04Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT03328897)
- 2020-10-29Phase 3 first posted: AO GENERIUM, Genolar® + Symbicort® + Xolair® + Symbicort® (NCT04607629)
- 2020-09-09Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT01723072)
- 2020-08-14Results posted on the registry: Novartis Pharmaceuticals, Ligelizumab (NCT02649218)
- 2020-06-11Phase 3 first posted: Celltrion, CT-P39 + EU-approved Xolair (NCT04426890)
- 2020-03-23Results posted on the registry: Hoffmann-La Roche, Omalizumab + Placebo (NCT03280550)
- 2020-03-23Results posted on the registry: Hoffmann-La Roche, Omalizumab + Placebo (NCT03280537)
- 2020-02-25Results posted on the registry: Novartis Pharmaceuticals, OMALIZUMAB (NCT02550106)
- 2019-12-26Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab (NCT04210843)
- 2019-11-27Phase 3 first posted: Sanofi, Dupilumab SAR231893 + Placebo (NCT04180488)
- 2019-11-04Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Placebo (NCT03369704)
- 2019-10-16Phase 3 first posted: University of California, Davis, Rituximab combined with Omalizumab (NCT04128176)
- 2019-09-30Results posted on the registry: NYU Langone Health, Omalizumab + Placebo (NCT02658877)
- 2019-09-30Also stopped (terminated): NYU Langone Health, Omalizumab + Placebo (NCT02658877)
- 2019-09-27Results posted on the registry: University of New Mexico, Xolair (NCT00189228)
- 2019-09-20Results posted on the registry: Andrew Long, PharmD, Omalizumab + Food Flour Allergens (NCT03181009)
- 2019-07-10Also stopped (withdrawn): Bernstein Clinical Research Center, omalizumab (NCT00242359)
- 2019-07-02Results posted on the registry: Novartis Pharmaceuticals, Omalizumab + Budesonide (NCT01912872)
- 2019-07-02Also stopped (terminated): Novartis Pharmaceuticals, Omalizumab + Budesonide (NCT01912872)
- 2019-07-01Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Epinephrine + Omalizumab (Xolair) (NCT00890162)
- 2019-04-09Phase 3 first posted: Novartis Pharmaceuticals, Ligelizumab (NCT03907878)
- 2019-03-26Results posted on the registry: David Lang, Omalizumab + placebo (NCT00555971)
- 2019-03-19Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), Omalizumab + Placebo for Omalizumab (NCT03881696)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision